Insider · CIK 0001661481
Helen M Boudreau
Files at PINC (Premier, Inc.), STTK (Shattuck Labs, Inc.), RLYB (Rallybio Corp). First filing Jan 7, 2025, latest Jun 2, 2025.
In brief
Helen M Boudreau files SEC Form 4 as director at PINC (Premier, Inc.), and also at STTK (Shattuck Labs, Inc.), RLYB (Rallybio Corp). Since Jan 7, 2025, Helen M Boudreau has reported 0 open-market buys worth $0 and 2 open-market sells worth $99k, the latest filed on Jun 2, 2025.
A track record needs three past buys with six months of prices behind them; Helen M Boudreau has 0, so none is measured yet.
The newest scored trade: sold $46k of PINC on May 30, 2025, filed Jun 2, 2025, scored 9 (weak), under a 10b5-1 plan.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
PINC: Premier, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 9Weak | Premier, Inc. | $46k 2,000 shares | -10% | - | |
| 7Weak | Premier, Inc. | $54k 2,500 shares | -11% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| May 30, 2025 | PINC Premier, Inc. | 2,000 0.00% of outstanding | $46k | May 30, 2025 | none |
| Jan 6, 2025 | PINC Premier, Inc. | 2,500 0.00% of outstanding | $54k | Jan 6, 2025 | none |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 6, 2026 | RLYB Rallybio Corp | MOption exercise Common Stock | +3,562 | $2.38 | $8,478 | 6,542 | Jul 10, 2026 |
| Jul 6, 2026 | RLYB Rallybio Corp | MOption exercise Option (Right to Buy)derivative | -3,562 | $0.00 | $0 | 0 | Jul 10, 2026 |
| May 29, 2026 | STTK Shattuck Labs, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +81,000 | $0.00 | $0 | 81,000 | Jun 2, 2026 |
| Nov 25, 2025 | PINC Premier, Inc. | DDisposition to issuer Class A Common Stock | -18,668 | $28.25 | $527k | 0 | Nov 26, 2025 |
| Jul 14, 2025 | STTK Shattuck Labs, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +33,150 | $0.00 | $0 | 33,150 | Jul 16, 2025 |
| May 30, 2025 | PINC Premier, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -2,000 | $22.88 | $46k | 18,668 | Jun 2, 2025 |
| May 13, 2025 | RLYB Rallybio Corp | AGrant or award Option (Right to Buy)derivative | +28,500 | $0.00 | $0 | 28,500 | May 15, 2025 |
| Jan 6, 2025 | PINC Premier, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -2,500 | $21.42 | $54k | 20,668 | Jan 7, 2025 |
| Dec 9, 2024 | PINC Premier, Inc. | AGrant or award Class A Common Stock | +7,101 | $0.00 | $0 | 23,168 | Dec 10, 2024 |
| Dec 4, 2023 | PINC Premier, Inc. | AGrant or award Class A Common Stock | +7,333 | $0.00 | $0 | 22,696 | Dec 5, 2023 |
Questions about Helen M Boudreau
Answered from the filings on this page, as of the latest one.
Is Helen M Boudreau buying or selling?
Not in the last 12 months. Helen M Boudreau's latest open-market trade on SEC Form 4 was sold $46k of PINC on May 30, 2025.
How did Helen M Boudreau's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Helen M Boudreau has 0.
Where does Helen M Boudreau file Form 4?
Helen M Boudreau has filed Form 4 at PINC (Premier, Inc.); STTK (Shattuck Labs, Inc.); RLYB (Rallybio Corp). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.